<SEC-DOCUMENT>0001193125-23-291662.txt : 20231208
<SEC-HEADER>0001193125-23-291662.hdr.sgml : 20231208
<ACCEPTANCE-DATETIME>20231208160252
ACCESSION NUMBER:		0001193125-23-291662
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20231205
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231208
DATE AS OF CHANGE:		20231208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EyePoint Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		231475342

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida Corp.
		DATE OF NAME CHANGE:	20080619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d613658d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eypt="http://eyepointpharma.com/20231205" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-12-05_to_2023-12-05">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-12-05_to_2023-12-05">0001314102</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="eypt-20231205.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-12-05_to_2023-12-05"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-05</xbrli:startDate> <xbrli:endDate>2023-12-05</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-12-05_to_2023-12-05">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(D)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-12-05_to_2023-12-05" format="ixt:datemonthdayyearen">December 5, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-12-05_to_2023-12-05">EyePoint Pharmaceuticals, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-12-05_to_2023-12-05" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-12-05_to_2023-12-05">000-51122</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-12-05_to_2023-12-05">26-2774444</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-12-05_to_2023-12-05">480 Pleasant Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-12-05_to_2023-12-05">Watertown</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-12-05_to_2023-12-05">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-12-05_to_2023-12-05">02472</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices, and Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-12-05_to_2023-12-05">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-12-05_to_2023-12-05">926-5000</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, including Area Code</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-12-05_to_2023-12-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-12-05_to_2023-12-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-12-05_to_2023-12-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-12-05_to_2023-12-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-12-05_to_2023-12-05">Common Stock, par value $0.001</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-12-05_to_2023-12-05">EYPT</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-12-05_to_2023-12-05" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-12-05_to_2023-12-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EyePoint Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued press releases announcing the launch, pricing and closing of its previously announced underwritten public offering of 13,529,411 shares of the Company&#8217;s common stock, par value $0.001 per share, at a public offering price of $17.00 per share, on December&#160;4, 2023, December&#160;5, 2023 and December&#160;8, 2023, respectively. Copies of these press releases are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and are each incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01. Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Exhibits</span>. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d613658dex991.htm">Press Release issued by the Company announcing the launch of the offering on December<span style="font-weight:bold"> </span>4, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d613658dex992.htm">Press Release issued by the Company announcing the pricing of the offering on December<span style="font-weight:bold"> </span>5, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d613658dex993.htm">Press Release issued by the Company announcing the closing of the offering on December<span style="font-weight:bold"> </span>8, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:46%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">EYEPOINT PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: December&#160;8, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ George O. Elston</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">George O. Elston</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d613658dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g613658g1209004537996.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WATERTOWN, Mass., December&nbsp;4, 2023 (GLOBE NEWSWIRE) &#150; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and
commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $175&nbsp;million of shares of its common stock. All of the shares are being
offered by EyePoint. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $26.25&nbsp;million of shares of EyePoint&#146;s common stock at the public offering price, less the
underwriting discount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan, TD Cowen and Guggenheim Securities are acting as joint book running managers for the offering. The offering is
subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of
<FONT STYLE="white-space:nowrap">EYP-1901</FONT> for wet age related macular degeneration through the initiation of and reporting of topline data from two pivotal Phase 3 clinical trials, as well as support its earlier stage pipeline development
initiatives, and for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above to be issued and sold are being offered by the Company pursuant to a
shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-275125)</FONT> previously filed with the Securities and Exchange Commission (SEC) on October&nbsp;20, 2023 and declared
effective by the SEC on October&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to
the offering that form a part of the applicable registration statements. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the
SEC&#146;s website at www.sec.gov. Copies of the preliminary prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, by telephone at (866) <FONT STYLE="white-space:nowrap">803-9204,</FONT> or by email at <U>prospectus-eq_fi@jpmchase.com</U>; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at
<U>Prospectus_ECM@cowen.com</U> or by telephone at (833) <FONT STYLE="white-space:nowrap">297-2926;</FONT> or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at
(212) <FONT STYLE="white-space:nowrap">518-9544,</FONT> or by email at <U>GSEquityProspectusDelivery@guggenheimpartners.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall
not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About EyePoint Pharmaceuticals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage company committed to developing and commercializing therapeutics to help improve the lives of
patients with serious retinal diseases. The Company&#146;s pipeline leverages its proprietary bioerodible Durasert E<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology for sustained intraocular drug delivery. The company&#146;s
lead product candidate, <FONT STYLE="white-space:nowrap">EYP-1901,</FONT> is an investigational sustained delivery </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with Durasert
E<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases. Additional pipeline programs include <FONT
STYLE="white-space:nowrap">EYP-2301,</FONT> a promising <FONT STYLE="white-space:nowrap">Tie-2</FONT> activator, razuprotafib, f/k/a <FONT STYLE="white-space:nowrap">AKB-9778,</FONT> formulated in Durasert E<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> to potentially improve outcomes in wet AMD and diabetic eye disease. The proven Durasert<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> drug delivery platform has been safely
administered to over thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that
is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the timing and success of the proposed offering, as well as the
anticipated use of proceeds for the proposed offering and other statements identified by words such as &#147;will,&#148; &#147;potential,&#148; &#147;could,&#148; &#147;can,&#148; &#147;believe,&#148; &#147;intends,&#148; &#147;continue,&#148;
&#147;plans,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;estimates,&#148; &#147;may,&#148; other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different
degrees, uncertain. Uncertainties and risks may cause EyePoint&#146;s actual results to be materially different than those expressed in or implied by EyePoint&#146;s forward-looking statements. For EyePoint, this includes satisfaction of the
customary closing conditions of the offering, delays in obtaining required stock exchange or other regulatory approvals, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and
the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market. More detailed information on these and additional factors that could affect EyePoint&#146;s actual results
are described in EyePoint&#146;s filings with the&nbsp;SEC, including its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022, as revised or supplemented by its Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christina Tartaglia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stern IR </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-698-8700</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">christina.tartaglia@sternir.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amy Phillips </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Green Room Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">412-327-9499</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">aphillips@greenroompr.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d613658dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g613658g1209004537996.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WATERTOWN, Mass., December 5, 2023 (GLOBE NEWSWIRE) &#150; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and
commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17.00 per share. The
aggregate gross proceeds from this offering are expected to be approximately $200.0&nbsp;million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the shares of common stock are being
sold by EyePoint. The closing of the offering is expected to occur on or about December 8, 2023, subject to the satisfaction of customary closing conditions. In addition, EyePoint has granted the underwriters an option for a period of 30 days to
purchase up to an additional 1,764,705 shares of EyePoint&#146;s common stock at the public offering price, less underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan, TD Cowen and Guggenheim Securities are acting as joint book running managers for the offering. Cantor is also acting as a book running manager
for the offering. Mizuho and Laidlaw&nbsp;&amp; Company (UK) Ltd. are acting as <FONT STYLE="white-space:nowrap">co-managers</FONT> for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of
<FONT STYLE="white-space:nowrap">EYP-1901</FONT> for wet age related macular degeneration through the initiation of and reporting of topline data from two pivotal Phase 3 clinical trials, as well as support its earlier stage pipeline development
initiatives, and for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are being offered by the Company pursuant to a shelf registration
statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-275125)</FONT> previously filed with the Securities and Exchange Commission (SEC) on October&nbsp;20, 2023 and declared effective by the SEC on
October&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities are being offered by means of a prospectus supplement and accompanying prospectus relating to the offering that
form a part of the registration statement. A preliminary prospectus supplement relating to the offering was filed with the SEC on December 4, 2023 and is available on the SEC&#146;s website at www.sec.gov. The final prospectus supplement relating to
and describing the terms of the offering will be filed with the SEC and also will be available on the SEC&#146;s website at www.sec.gov. Before investing in the offering, you should read each of the prospectus supplement and the accompanying
prospectus relating to the offering in their entirety as well as the other documents that EyePoint has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which
provide more information about EyePoint and the offering. Copies of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) <FONT STYLE="white-space:nowrap">803-9204,</FONT> or by email at <U><FONT STYLE="white-space:nowrap">prospectus-eq_fi@jpmchase.com</FONT></U>; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at <U>Prospectus_ECM@cowen.com</U> or by telephone at (833) <FONT STYLE="white-space:nowrap">297-2926;</FONT> Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th
Floor, New York, NY 10017, or by telephone at (212) <FONT STYLE="white-space:nowrap">518-9544,</FONT> or by email at <U>GSEquityProspectusDelivery@guggenheimpartners.com</U>; or Cantor Fitzgerald&nbsp;&amp; Co., Attention: Capital Markets, 110 East
59th Street, 6th Floor, New York, New York 10022, or by <FONT STYLE="white-space:nowrap">e-mail</FONT> at <U>prospectus@cantor.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g613658g1209004537996.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state
or jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About EyePoint Pharmaceuticals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage company committed to developing and commercializing therapeutics to help improve the lives of
patients with serious retinal diseases. The Company&#146;s pipeline leverages its proprietary bioerodible Durasert E<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology for sustained intraocular drug delivery. The company&#146;s
lead product candidate, <FONT STYLE="white-space:nowrap">EYP-1901,</FONT> is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI)
with Durasert E<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases. Additional pipeline programs include <FONT
STYLE="white-space:nowrap">EYP-2301,</FONT> a promising <FONT STYLE="white-space:nowrap">Tie-2</FONT> activator, razuprotafib, f/k/a <FONT STYLE="white-space:nowrap">AKB-9778,</FONT> formulated in Durasert E<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> to potentially improve outcomes in wet AMD and diabetic eye disease. The proven Durasert<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> drug delivery platform has been safely
administered to over thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that
is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the timing of the closing of the offering, as well as the
anticipated use of proceeds for the offering and other statements identified by words such as &#147;will,&#148; &#147;potential,&#148; &#147;could,&#148; &#147;can,&#148; &#147;believe,&#148; &#147;intends,&#148; &#147;continue,&#148;
&#147;plans,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;estimates,&#148; &#147;may,&#148; other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different
degrees, uncertain. Uncertainties and risks may cause EyePoint&#146;s actual results to be materially different than those expressed in or implied by EyePoint&#146;s forward-looking statements. For EyePoint, this includes satisfaction of the
customary closing conditions of the offering, delays in obtaining required stock exchange or other regulatory approvals, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and
the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market. More detailed information on these and additional factors that could affect EyePoint&#146;s actual results
are described in EyePoint&#146;s filings with the&nbsp;SEC, including its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022, as revised or supplemented by its Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christina Tartaglia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stern IR </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-698-8700</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">christina.tartaglia@sternir.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g613658g1209004537996.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amy Phillips </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Green Room Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">412-327-9499</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">aphillips@greenroompr.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d613658dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g613658g1209004537996.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Full Exercise of Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WATERTOWN, Mass., December 8, 2023 (GLOBE NEWSWIRE) &#150; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and
commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the closing of its previously announced underwritten public offering of 13,529,411 shares of its common stock, which includes the exercise
in full by the underwriters of their option to purchase an additional 1,764,705 shares of common stock, at the public offering price of $17.00 per share. Gross proceeds to EyePoint in the offering, before underwriting discounts and estimated
expenses of the offering, were approximately $230.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan, TD Cowen and Guggenheim Securities acted as joint book running managers
for the offering. Cantor also acted as a book running manager for the offering. Mizuho and Laidlaw&nbsp;&amp; Company (UK) Ltd. acted as <FONT STYLE="white-space:nowrap">co-managers</FONT> for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EyePoint intends to use the net proceeds from the offering to advance clinical development of <FONT STYLE="white-space:nowrap">EYP-1901</FONT> for wet age
related macular degeneration through the initiation of and reporting of topline data from two pivotal Phase 3 clinical trials, as well as support its earlier stage pipeline development initiatives, and for general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above were offered by EyePoint pursuant to a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No. <FONT
STYLE="white-space:nowrap">333-275125)</FONT> previously filed with the Securities and Exchange Commission (SEC) on October&nbsp;20, 2023 and declared effective by the SEC on October&nbsp;30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities were offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration
statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC&#146;s website at www.sec.gov. Copies of the final prospectus supplement and accompanying
prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) <FONT STYLE="white-space:nowrap">803-9204,</FONT> or by email
at <U><FONT STYLE="white-space:nowrap">prospectus-eq_fi@jpmchase.com</FONT></U>; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at <U>Prospectus_ECM@cowen.com</U> or by telephone at (833)
<FONT STYLE="white-space:nowrap">297-2926;</FONT> Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at (212) <FONT STYLE="white-space:nowrap">518-9544,</FONT> or by
email at <U>GSEquityProspectusDelivery@guggenheimpartners.com</U>; or Cantor Fitzgerald&nbsp;&amp; Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by <FONT STYLE="white-space:nowrap">e-mail</FONT> at
<U>prospectus@cantor.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities
described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g613658g1209004537996.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About EyePoint Pharmaceuticals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage company committed to developing and commercializing therapeutics to help improve the lives of
patients with serious retinal diseases. The Company&#146;s pipeline leverages its proprietary bioerodible Durasert E<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology for sustained intraocular drug delivery. The company&#146;s
lead product candidate, <FONT STYLE="white-space:nowrap">EYP-1901,</FONT> is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI)
with Durasert E<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases. Additional pipeline programs include <FONT
STYLE="white-space:nowrap">EYP-2301,</FONT> a promising <FONT STYLE="white-space:nowrap">Tie-2</FONT> activator, razuprotafib, f/k/a <FONT STYLE="white-space:nowrap">AKB-9778,</FONT> formulated in Durasert E<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> to potentially improve outcomes in wet AMD and diabetic eye disease. The proven Durasert<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> drug delivery platform has been safely
administered to over thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that
is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements
identified by words such as &#147;will,&#148; &#147;potential,&#148; &#147;could,&#148; &#147;can,&#148; &#147;believe,&#148; &#147;intends,&#148; &#147;continue,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;anticipates,&#148;
&#147;estimates,&#148; &#147;may,&#148; other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause
EyePoint&#146;s actual results to be materially different than those expressed in or implied by EyePoint&#146;s forward-looking statements. For EyePoint, this includes stock price volatility and uncertainties relating to the financial markets, the
medical community and the global economy, and the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market. More detailed information on these and additional factors that
could affect EyePoint&#146;s actual results are described in EyePoint&#146;s filings with the&nbsp;SEC, including its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022, as revised or
supplemented by its Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint
undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christina Tartaglia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stern IR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">212-698-8700</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">christina.tartaglia@sternir.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amy Phillips </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Green Room Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">412-327-9499</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">aphillips@greenroompr.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>eypt-20231205.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/9/2023 12:40:50 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:eypt="http://eyepointpharma.com/20231205"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://eyepointpharma.com/20231205"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20231205_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20231205_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>eypt-20231205_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/9/2023 12:40:50 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>eypt-20231205_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/9/2023 12:40:50 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eypt-20231205.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g613658g1209004537996.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g613658g1209004537996.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M .<# 2(  A$! Q$!_\0
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MDO+@2WA29HVND>.0CT;K7#7-M+:SF*888<@CHP]17H.O6+:?K5U 1@"0E?\
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M ^I)JW:26MK#T:,[XJN+[Q%X4TF [[IKOS"@ZA2RC/Z'\J=\8?\ 6^&/^O\
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IWWL;DM/&J9\MAP,'/?.,<4O9O<+'I%%%%9$A1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139785913202064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  05,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EyePoint Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2774444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Pleasant Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-5000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYPT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d613658d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eypt-20231205.xsd" xlink:type="simple"/>
    <context id="duration_2023-12-05_to_2023-12-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-12-05_to_2023-12-05">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-12-05_to_2023-12-05"
      id="Hidden_dei_EntityCentralIndexKey">0001314102</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-12-05_to_2023-12-05">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-12-05_to_2023-12-05">2023-12-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-12-05_to_2023-12-05">EyePoint Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-12-05_to_2023-12-05">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-12-05_to_2023-12-05">000-51122</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-12-05_to_2023-12-05">26-2774444</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-12-05_to_2023-12-05">480 Pleasant Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-12-05_to_2023-12-05">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-12-05_to_2023-12-05">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-12-05_to_2023-12-05">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-12-05_to_2023-12-05">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-12-05_to_2023-12-05">926-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-12-05_to_2023-12-05">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-12-05_to_2023-12-05">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-12-05_to_2023-12-05">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-12-05_to_2023-12-05">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-12-05_to_2023-12-05">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-12-05_to_2023-12-05">EYPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-12-05_to_2023-12-05">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-12-05_to_2023-12-05">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %F B%<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !9@(A7R^O=>.T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TU1)'1S43PI""XHWD(RNQMLTI",M/OVMG&WB^@#>,S,GV^^
M@>E,E&9(^)R&B(D<YJO)]R%+$S?L0!0E0#8']#K7<R+,S=V0O*;YF?80M?G0
M>P3!^0UX)&TU:5B 55R)3'762)-0TY!.>&M6?/Q,?8%9 ]BCQT 9FKH!II:)
M\3CU'5P "XPP^?Q=0+L22_5/;.D .R6G[-;4.([UV);<O$,#;T^/+V7=RH5,
M.AB<?V4GZ1AQP\Z37]N[^^T#4X*+MFI$Q6^WHI%<R&O^OKC^\+L(^\&ZG?O'
MQF=!U<&ONU!?4$L#!!0    ( %F B%>97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M68"(5^.<9_=+!   D1   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R-
MF&]SXC80QK^*QKWIM#,)MLR_) 5F"$G:S%UR7*#-M)V^$/8"FMB6*\LA?/NN
M#+&YQJS)BV!C[>.?5JM'$H.-TB_9&L"PMSA*LJ&S-B:]<MTL6$,LLI9*(<$G
M2Z5C8?!6K]PLU2#"(BB.7-_S>FXL9.*,!L5W4ST:J-Q$,H&I9ED>QT)OKR%2
MFZ'#G?<OGN1J;>P7[FB0BA7,P/R>3C7>N:5**&-(,JD2IF$Y=,;\ZMKOV("B
MQ1\2-MG!-;-=62CU8F_NPZ'C62*((#!60N#'*TP@BJP2<OR[%W7*=]K P^MW
M];NB\]B9A<A@HJ)G&9KUT+EP6 A+D4?F26U^@WV'NE8O4%%6_&>;7=N.Y[ @
MSXR*]\%($,MD]RG>]HDX"&CS(P'^/L ON'<O*BAOA!&C@58;IFUK5+,715>+
M:(23B1V5F='X5&*<&=VH(,<D&R:2D-TF1IHMNT]VHXU9&[@&7V*;NL%>\'HG
MZ!\3A*#%O.X9\SV__7VXBVPEH%\"^H5>^XC>1+V"9G^/%YG1.(3_U!'M%#KU
M"K:NK[)4!#!TL' ST*_@C'[\@?>\7PB^=LG7IM1'8\Q>6&3P+A*K.CHZ?BFB
M# B.3LG1(77V8S=!$BTB',,0WMAGV-81T4J>Y_$V[W#/)["Z)5:7%"OK:[Y-
MH8Z%#K\X_TQ ]$J(WFD04]!2V3H/&<Z66IX&)5O=17DWU7>_9.N?,FY/L)*V
MPA'R4<2U9 TZ6Y@J:?NX%CAY \B-#+"VSK 4@A8!>E&"7IP"BFI*ITH7]L!F
M!M/()BK'JL/B4V$M.2U\<TO0799TEZ?0W<D(V&,>+T#7@= :6/CG7<Y]JNZY
M5QFK=PK17+RQ^Q"+3RYQ/(JD'>=KD/1[YWZ_W\$_BO# ^ODIA.,P1%O$0ME?
ML"_8CGU-:H>R0;)SX;%I!"*SA8P/<%FB4*M%@),>_@%U8N^49G.UJ5^C:+EG
MK%IM/L1^#U>M )RV\/_#[28%TDVU>I5)4)](6O-A3*%5BP(_:54HT:8J,[@Z
M_"73HY.U0='S.WUR@E0K Z>]O1C#,6XECZ/0 C_U>/]G"J5:'SAMZU\46B4Z
MITHH]V@0N<3IV44/H8BJ58'3=OZLI3&08&KB.$_VSI'54M%"3?L+7OD_IWUZ
MIB(92".3%7NP\T>*J):'5FGDJ1R?TW8]U5"D!W"&[;88N!/#O>+7Y?+(^-%Z
M361^9?T^[=,?R.ZS+$>R)L &V4; ROE]VJ9G$.3:3C_N+]A<FJAV^C6(V!X6
M6P 5O)RQ5&CV*J(<V">OA3M(BO-@[T_[]%R+T-;;;!LO5&VU-0C<_CF=4R25
MQ_NT'Y<9NWT+UB)9P=%M6H/0XWAV,_Y&,57F[I]D[K<QZ)7-TJ^H8-:V\E*1
MU&[\&P2/%IA[<,"TA_4'8=^8L0B6*.2U^FC4>G?^W=T8E19GSH4R>((M+M<@
ML/AM WR^5,J\W]AC;/DKQ.@_4$L#!!0    ( %F B%>?H!OPL0(  .(,   -
M    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58
M=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C
M<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+
M#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\
M0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9
M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M68"(5\OKW7CM    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ 68"(5YE<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !9@(A7XYQG
M]TL$  "1$   &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ 68"(5Y^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d613658d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d613658d8k.htm">d613658d8k.htm</File>
    <File>eypt-20231205.xsd</File>
    <File>eypt-20231205_lab.xml</File>
    <File>eypt-20231205_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d613658d8k.htm": {
   "nsprefix": "eypt",
   "nsuri": "http://eyepointpharma.com/20231205",
   "dts": {
    "inline": {
     "local": [
      "d613658d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "eypt-20231205.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "eypt-20231205_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eypt-20231205_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-12-05_to_2023-12-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d613658d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-12-05_to_2023-12-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d613658d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://eyepointpharma.com//20231205/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-291662-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-291662-xbrl.zip
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MJRZ'"H(\8=#.J(/_:ZY==GV>^OTR$_R$=SVF*<$>4NSO/G^Z2I2%IYFG4RW
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MAL1UN<OLKP1B04)]7PI?<HP/VV)(VLP5 UPU+,3%7"VV9G_5R!'I<!?QR16
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MKQ#<TCN>>1U>WC-3GRXYCQH _3XJKR?FCM(P!9^/)P0*=9;#D@&M&D(9X!-
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MR4X1*!43 ;$.0C4'NH"I+]>5>JN&]$X[V]:6<S #RX)TP FL '%)P#4NAYL
ME&R,Q5.MDLG4L@3BL73+4"N94XM(Z3C%#*B0B@'$8,Q3.>:(1'FG8K!\;<.Q
MN90AUM*"*0PX%]  ?IHDHOLLO BN PE/,#'Q&,E(N,N7DA<+&4-WA'W$#XGE
MF _@)AJ703(" TI+YN<''P6$6<:6+XRGY8@@=V0Q79'_2OB\16&?&17X2Z!D
M*SA)^CY)\PGX-XG%0K@"@FPJ@C%4/Y$F3JT$)<7">4/(3E&%L6<]8E!I9LZP
M=:FJSQ]H-IN5QMY.O;'S)CL8:7%'F2A8L+$,P+A-3\3Z*L! SMYWH'$XL2+-
M(#_QO#7HG;PA?J^\6.5)N5%+LS(=\X4'AQ3(F@*:\<C0F6YP^-[99GKVU>UL
M(W@D5NTW$SRTZ,,IX$T$[A/GX($S%,G'O;1D< DDWV8CTL5^L; .!H098S(P
M[N4ZSO"-XUY$U2@0CS@&G+]#]@KD##6#7CS!E</29SE++60]/"UD'L;<7#V;
M/@(3TAW9U_R.R\"*8'$'*10[LA0\%R,#GZ3L.Y_/JU!^=:+NJG"H2(J<Y+,"
MEEU:R4F57VJ'!S.1&L4<H.0[M%O)O*O^?WY^4F;>MF+'6G%?2Q]A< H60ZH!
MV4 %B4V/95:O[^RP<T4%4]\$Q%?G3H0)>.SAS%PI)+S++]BV5]\KVS@0@8BF
M*K1:V=K?W7WS?!3OUYJ55J/VMIS%,! 35XD9%$+7''UL+Q50$=_^',OW7Z.9
M+::JT-+1]L?VX4I1D6)4V8FYTVJQ<_$=*HIAPXQ]"IPO2M\Z]FNU1J.\2A/I
MZV/[.B?Z9^_DXKU'!#)Z*8\;XC:;+Q"WT=JK-%J-W<,5<1^L@U(!.E00DSU0
MUG]+9+Q@@P4*&(_22%=0Q#DO:J+6O."HZE;$W(=?GP9*Z?L2D\'N"U$L;#7J
MC1=(L5/?K[1VWCYEM+.!XW>IQZZ@]D$OWD]R>8E_)$>3*?8U@%(:BDIC@XFZ
M%"JS@Z!8")4M#DTLXX3B.G311:%FJ!Q(BTUD2.G)>*7J6.X;)=3K+/*^XZ'$
M2_6F1"4<XCY+.2U!"6]PU'""&WO>K-T@0_<]X2?Q\A5?&#B"Y0-?PDP>.K$$
M?UE^RAN<:G?U7"7(\"-J80(^'R<0'(V"LNRO 366OJ%ZE6/R-5JP[<.F7+C#
M)15BC6@_R-^39MW_$68].FYW1BJ)'^V1G^OP=W]HI;U)?.N2&Y]_2UMS%%S4
MG*=U9\45E"_HU=ESK3KJL.C!?AU&?E'#[CJH%$*S3)>7N@&XT>#5V'H85. Y
M(J;4-I)*:.5+RI5=]$^X'Z8X&GQ\8("UM_./0X:+K&HJ=N9V  N4VC3E: (7
M<:H-6/*FH0K49&%K:).8-+-!O9JKM#'0"3K9%%8<[]X:[\4"0MPG5OT$72#:
M/%^B&P VOKA!R2%.VDY?AM!H+"<\;=V7C&5\9 W==K?_"1Z7#AV+!6;_'$4(
MD44@UF- S.XY'RU%4'9EI 6_K8P$U" .>##G"U-"+&U'1.3##1OT_PT1FJ7L
M7CL4/?BE9?\KL<_][O##NQ(P_Q_Y$.VD=SGLW?S/C45Q>0QA;4:S5O_4.SNM
MS(0O;3NXZ:QD:Q1Z% AW2BL4*')$4R^@=5J:4\S \7%=!2X E[)AM4!&(G>^
MQ6V&FD@[>@6YK>'O_3<N0#(G+A;^&R^NLD\98^0^@&,1&A?9.52([UZ0&'"+
MGH7&44B:H?K.!IX4=H29#3D"Y5'8T^E<1P2\E)FB*<KP8":]E4#N+,=+>0!#
M"1/-9Y1,0-07:12@KGTZ#AK-E3BP_0-Z)M+[LU$TE*+2R$^257A,]8CF?R5D
M$CXFFXVW;[?Y\Y=U?C^NM/;V]LLK0X-9XF8%R( ;P)-+];>A1[%(V:H+REWD
M>(KL H=SF9@F%9V+KNLX)!_!,STF%B+3O\,B>V[)U]]U)*3CC*4UH&,11+8M
M%TU11P(D#!_#?XH%[J/70 ZW31_D 'WR'D ]I\'/<G!+S +//(0"N5BBV<?J
MH,I.NQWJW(CO'#7A2X_F-3CU% "+0D$[FM#-9]A#QVH>NBDW]Z:)$7%L7F'2
M->B<]MB'SLWQ%6!QV!GV+@!T _;QLMN[8<,//79]T_^$9>KT/M[TA_W>@)WC
MQUEGV+^Z9)V3(;LZ9?56:^> #5V');['K@U=K+2N8-0GX,".>]6D+Q!Q%D-D
M2$;*IE9476,S59DXA" @#9;3.H\F+M@\Y]JOH&"_I=A:(;<LO:XU1=#:..-<
M9NF(W0CK%AW/0@/)466#O"IS=Z6ACX8'U1+1)8ZH1W4E1WEU+SP0'.6]-#6R
MKA!!J>>1T'F7FSZS9/WHVA#-=LX<X>3)R,8J#1_)%;.Y8P9Q]ZZQM)2=OZY*
MX%-LCJ6;:\R5]HVK/4&+\O[>(37P9?IU_S!=R0-Z?=FC:GACB8?K"R.$'0J?
M]<5TE+IY&TA0Y^56BX64-A+ QD[QG5JBC<6EBC9WH^"8W5]&SY\M.!TY5=##
M 2Q%]1'-?.P8S^DWU?LXB1-MIZ*4)TX?=SLWV9*:A=R>X+YO71V\V(</._N!
M"Y5MJ2KMK(FFH+Z8:$$=++WY:"J/JNQC]FL^@D-[<&OLX,+CQ-GF&T<Z/0?%
M)(A-.JHD-6B'RSE!XH,B#*Z#<+71Z) (8@.\ [G^T)/=_WB\6:7D^\LNRM.X
M@:LAULR8>UD#:-W;0QD(# (X>X&RJ7'EG6%C_%0F)*=G(6+1#FQHOQ;(_ 2A
M[E%'9 -*<.*LBV"D7*= PT&T'5:[W?:M!U4038<"&A*0@I,UE6^.CL;YQ,<]
MC!B+18RJ+<\.JV>S),RNHF\F@1KA"P'!U&Q1=H^'=@J/BMLACD3WS$>. PB7
M#;Y'"=5;QIG=G4>Z7"JHG"K7JLU*;74#_ RX>XVC<(-=8T;C\_SA!MWG".IQ
M_-M)%\$O) ZL_9?HZ\9WQA6$*^]N9$65.;+% L;M7/<99P2<65)93P]F[WD7
MM!!.3#Y<= -AY)U58:F-ZH0AW7QC'RY>/BVOURJ_K[Z=.),:,MU"(/2!3F!L
M_7VY6;?CZ(9%9YJ46ZS5*]-(%RG$UA\NI2/.'&?PXK!8>#%O?^0U7X[@/IHV
MAROWQZ[NN?:)#)CEVE#,5P8W$3HC\ 4F>1YEOIT_C.]O7REC;#Z-^:V@?(P8
M#+($2B]CD9].,)R&*/47"X^R5LY?"#DU]<Y!B#Y(K_I@.8-=I!(2* OKN23.
M7F$\TK>-*[S]X%5&(2=3X#OU:VP(1^*30/(GI/PAW>, _AJR_LU3=>8/(=0%
M3GOQP?.!\/PTN-ZH[+;V*_M[M5H:,5G@_&PAO,Q U3@ST'MJ'$*I:1K[&BYY
M09T].\$NRA^OX96=V0(]#/T+B\C\;'<\T]29W2CH\L0E4S=(-?]'_OD6_MEL
M[%5:;UNM5_9/'J5V>D_%9*BAQVCIF0_/U^!"5]TO6+3_GO _4$L#!!0    (
M %F B%<@''_44@\  *DN   1    9#8Q,S8U.&1E>#DY,BYH=&WM6FE3VT@:
M_DX5_Z&+V9U*JF3C P,&XHH!0[S#-=@DF_VRU9;:=@=)K5%+.,ZOW^?MEF39
M'&9GDU1M[4YE"MSNXWGOBZ,/P\N+SM&'7O>TL[EQ-.P/+WJ=WM\K[7:U<;1M
M/V)].]O CHZO3S^SX_.3ZXOKVW=;GS[TA[TM-AA^ONB]V_)E*"I3(2?3Y.!*
MQ0'WMSIL<P/G3T28B+AS=-K_F&^>22^9'NQ76S+<8MR7DQ 7B'&R99ZYR;<%
M/)[(L)*HZ* 6)8<L^SQ22:("NS1685+1\ILXJ"\^CWD@_?G!4 9"LRLQ8[<J
MX'BI>]$_OWJW%1/(K<[1<:?W=2I',F%$,3O:/NX<;=]T2@!*MS=P^PJ>1W"V
M.K^&(QT=TBT@_#DZGCA'C,*)_N4Y&]R>O-N:[-:;NZW]2;U1:]=J.ZWF7KN]
M6_T238B(X;NMB^OS:\NL9<"EEPSB-2S;>2W+7"-#R[.YN%$R3-C-E$/,KD@3
MZ7)?LVX8JC1T<?XFEJX,)TR-V5U$+WGL)AWYTF77X[&(Z:N<V<^PZ37@U\J[
M\ZD[[-T.KS]=.>R2:UUUV*EP13 2,6LYK%%K--F;\XOKXQZ[ZGT:?.K?]MZR
M7W^IMVJ'[#DJ'=8/W2I[<]4=G'9_/V"]SS?#MP[CS%5!Q,,Y_0QDDH#D1#%/
M/ A?140P#[W-#?I2Q*Z$RG^CQ60J8AZ9NS7MET$4JP=!Z\R7#Z &+(QX(L%^
MS68RF3(-_JE4LU@D,N0^\Z067 L 2Y3'YWC'2L$SET0+2?"0I:$GXEE,\$(6
M68FH7"+84J\[>[L[SEYMEVF0;9^7>)EPJY#I1+GWC"<@=_4T/21H^U_J>]5:
MC47@L;FCRH93L;G!)Y-83'@BV"166F._<H7P-!O'*@!4J1=WX1037R/A9EP<
M"<8C'/@J US@S]E?&K5:M69M#9+WI0H=[!HK'/2$E[H)75-02Q_ )A=\ 2T0
MA!62UCAG/RL2Q ( /1Z"IV#]G(]\P4;S0B&JK.O[1"BQ=\&E90X!QTC@ILT-
MK7QO^3C8P5Q?Z8SG=$WQ,+A0)ERY;@I8(5,QXR.5)@O]W;?ZZS"=CK[@ &TW
MB* L>LS! 3H&7"D@P8[FQ9NN"CU)7^LJ=)EQSWYR%BH_Y1I2XF&2*5'!2!$3
MNYB*S.UC0D6"ELJCIYHU!@4D/=[<B-+8Q34X&Q$ROG@'*IMK6:O$O_QQF-_.
M[N%CC3/*_)3..<P7T*?7";O*?KC/^5OUILHN53SA8.GPE)VH&8R-<)RGDXD(
M$2(#-A 0++#B*.D*MPH+MG\Q A@I=<_B- QI%;?R"7&>^%W6EBH[@8RP"*V!
M9U*E:_B35VQN/+[B4GY+I\K@N^#2\_G,FM6O/(@. =XZM3=WO[UE%XE778%[
M='9]-2R"^A0:4M$1G.5!J&9P;%L=5U5R_$?;M+GS!!D_7":%9N-_$7K&U:;:
MNME0) MGE$RA:L@'9G J\+"N@ _./53)3$FCO0<.+PNKDB$%AMS5!_#4V AR
MUK$&D:-2;]?J9;[,  ;,PM,^)^M#X$E]'N-R: Y"A;&[9!JK=#(UD/!X(GEN
M["3%6$0J3G+GHB+*RV"7"<_HF"D6R0>5 /*-L=#F@H8DEB;$0;(S 0[@ITXC
MNL]$ <%C7Y)?3PAC)"-A+U]0OKF1 WJ@B$1XB"P+WH<EQKB,@@#\0Z3@8:O_
M80*S7O;D;O7"W#RAW5B.P%LX5 BW<-56NL(X:^)LKOI JE/8F1$Z');PQ^#Q
M1.K$B@,N/@%%5NXA.T/JN]XL!I5F+O8W5ZJZ_D"SV:PT]EKU1NMM?C"*Q0-E
M HB'8^D#N$D/"'K9NT "O:]PQ>'$D)0Y0O9FT#MY2WBOW40AGEBC;]2RK(B.
M><*%ZN%> <:X)-&<-3C+B/"EL\WL[$^7Z),2# 0/35SA9-R:0FIJE=FWHB(*
MN9LE;3:8%-N,]65VOFSW< _&B09T+X^3/("7%8(5^H!4@:3DRP"9&B+PTTB>
M?6T&\UN5K.'\(@O8*<F+HL #E[Y)6(R;,/OS@#H3(PV]HE@ZF\VJ8&!UHAYL
M.C(VF>1:>,CBC%X8"\K25X:D(-"/$AGC0$?B*?R&\Q2N\CU_!O6Q3?9D"#]C
MT,EP"8##YBJ%M:K4)Y?(H<7<G>8PGU<)^K:L%LAD7J$7]G$9,UPCD9C/RQ[4
M[#3YI:?<-#"9O(DS2_G6$XPRF[BALG"<1KEC07I.T2>C^O7TO$;-'08/Y$X-
MZ0_2$RRPK":]MQIN<]$"?_Y0*3%!S2,*K7A!O>@M2H]R%7#^G&$&*'R@26J4
M<$0DSX:Z4B96=HD7%R<.<[<5.XX5]V+IP3.> 6%(9=GFQD#YJ<F.'91#K1:[
M4+B_KWW"U7T080J,/9R9*>4Y[.HS=NW5]QSC&X4OHJD*C;J^V=_=?;O>L>_7
MFI5VH[;CY&X=X1)7B0 ,H6N.[CIK[UAPJ"+^^.=8OO\2!2;[KH*-V;U'VW>=
MPU(RFH4WQ[*CU6YO;ER(K^!E OGF=)+3_:SB>TMGK=9H.*O@;HJW_]D[N7SO
MT@/VV;N<EA6V-)NO8$NCO5=IM!N[ASE;GDR>,_1=JF=)9BC'_T@ES&\P1XWC
M4J)Q*LA/6U5KHD*YY"@.2B3N)U#T,U^I^#&Y)-:G2&C4&Z\@H57?K[1;.R])
M]GQ@\2Z8>"JH[(_G[R<%O80?Z9/.N7I(%V69_YE,ODTHM?*6L_;J$E-.>"0I
MW[OD\;U(C&+76(]KQ+)6&PYGD,1"@#^[^/TQ*[+?<OE;*M92+RI$9TZZ)7>A
MI^]=@S\GJ2@!MD_['Z&J6<=P<X.9?T<18NK<%\NYA @>I1*T%"$WK8S@\N\K
MMB-PP/T9RM(MY"3;$3WRX98-^O\ [N96?J_I:![\TC;_;;%/_=/AAW=;H/BO
M10?LI'<U[-W^R9[F2UW-[]\-C%[[$BMG7ONK_<L?UXA%"B>I!42%.WPZ]:^H
M%8!X&:J$&A2(Z4E*83^T/IX<OJ9XFM6.6OG2A4XO"I_%OE%*3;!Y%GR0GC^5
M_",<(V5T\%Z<O4P16IAT!&<U]T5V@5Y*-F5HOZ<4C\!\P1<:KL8 P9<F<B*^
MF5P#@)P5J+&]>F;RDA&U5E!QCU.*CE(9^$NI));^2*%+8W)FM&#:')8%"U"X
MPN:ZA(R>-O V-U;PO9B9[W\/L1X==[K+J<%JCWA-VW?WNU;[JX^_N>+:XW]D
M35N3,!>U;\46M:_HXK)U35R4B-&3G5QD5*]JY=JD/(O0>29<E-L^T,3 JDU-
MCE>@.B*A^F(DE8B5)RF5/DUC7(4*I7<TN'MBGK'7^NLAPT6&-17CK@X@ 7B
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M:>>#*XL+SJSN1I0,'B\'?)XO6!Y95H"A&J*AH$X-5",4R]:,W>,T26,S3J#
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MI/'BAAWX9[.Q7VGMM%J_UC]YD-CI S5POH8:@S7/? + A0==];Y@T?Q)Y/\
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M/8[K;ON2]8/,-B>YNQE.?'O5;ASZ^0M02P,$%     @ 68"(5W:"]<U9!@
MOT,  !4   !E>7!T+3(P,C,Q,C U7VQA8BYX;6S-G&]OVS80QM\7Z'>X>6\V
MH+)C9WL1(TF1.<D0+&F"QMV&#4,A2XQ-3"(-4D[L;S]2?QHYIF0J/$UYT5:1
M[IZ[1_Z=2LMRCC^NXP@>B9"4LY/>L'_0 \("'E(V/^FMI.?+@-(>R,1GH1]Q
M1DYZ&R)['T_?OSO^SO/@_/+J$WBP2)*E' \&3T]/_?"!,LFC5:(D93_@\0 \
MKXB?3+_ [UFY,7PF$?$E@=B7"1'PRXI&X7AT,#H<'@Q'_5$Y31!?ZT'H)V0,
MP]'@:* #U=;XIX/QSP=P=@,7J0R#*8U).9<O-X+.%PG\$/P(:=8Y9XQ$$=G
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M4$L! A0#%     @ 68"(5\P9)U[J#0  5B@  !$              ( !WPX
M &0V,3,V-3AD97@Y.3$N:'1M4$L! A0#%     @ 68"(5R <?]12#P  J2X
M !$              ( !^!P  &0V,3,V-3AD97@Y.3(N:'1M4$L! A0#%
M  @ 68"(5^>07Y8.#@  &2D  !$              ( !>2P  &0V,3,V-3AD
M97@Y.3,N:'1M4$L! A0#%     @ 68"(5Z5J*XX_ P  4PL  !$
M     ( !MCH  &5Y<'0M,C R,S$R,#4N>'-D4$L! A0#%     @ 68"(5W:"
M]<U9!@  OT,  !4              ( !)#X  &5Y<'0M,C R,S$R,#5?;&%B
M+GAM;%!+ 0(4 Q0    ( %F B%<=&);[M00  ($J   5              "
M ;!$  !E>7!T+3(P,C,Q,C U7W!R92YX;6Q02P4&      < !P"^ 0  F$D
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
